Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
1.180
-0.010 (-0.84%)
At close: Jan 31, 2025, 4:00 PM
1.150
-0.030 (-2.54%)
After-hours: Jan 31, 2025, 6:11 PM EST
Femasys Revenue
Femasys had revenue of $554.91K in the quarter ending September 30, 2024, with 127.09% growth. This brings the company's revenue in the last twelve months to $1.26M, up 15.33% year-over-year. In the year 2023, Femasys had annual revenue of $1.07M, down -11.13%.
Revenue (ttm)
$1.26M
Revenue Growth
+15.33%
P/S Ratio
20.51
Revenue / Employee
$37,078
Employees
34
Market Cap
27.02M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.07M | -134.25K | -11.13% |
Dec 31, 2022 | 1.21M | 26.53K | 2.25% |
Dec 31, 2021 | 1.18M | 141.77K | 13.66% |
Dec 31, 2020 | 1.04M | 108.85K | 11.72% |
Dec 31, 2019 | 929.06K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
FEMY News
- 2 days ago - Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control - GlobeNewsWire
- 16 days ago - Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment - GlobeNewsWire
- 2 months ago - Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment - GlobeNewsWire
- 2 months ago - Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control - GlobeNewsWire
- 4 months ago - Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program - GlobeNewsWire
- 4 months ago - Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments - GlobeNewsWire
- 4 months ago - Femasys Announces Infertility Clinic Customers from Coast to Coast - GlobeNewsWire